Clinical trial
Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Capsules and Topamax® 25 mg Sprinkle Capsules Administered as 2 x 25 mg Capsules in Healthy Subjects Under Fasting Conditions
NCT00905164 is registered in ClinicalTrials.gov with Teva Pharmaceuticals USA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Capsules and Topamax® 25 mg Sprinkle Capsules Administered as 2 x 25 mg Capsules in Healthy Subjects Under Fasting Conditions
- Lead sponsor
- Teva Pharmaceuticals USA
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2002
- Completion date
- June 30, 2002
- Enrollment
- 24 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy